Matinas BioPharma Holdings, Inc. MTNB
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 0.00 | -- | -- |
| Gross Profit | -- | -- | 0.00 | -- | -- |
| SG&A Expenses | 1.56M | 1.94M | 1.60M | 1.58M | 1.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.56M | 1.94M | 1.60M | 1.58M | 1.84M |
| Operating Income | -1.56M | -1.94M | -1.60M | -1.58M | -1.84M |
| Income Before Tax | -1.33M | -1.92M | -1.91M | -1.53M | -5.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.33M | -1.92M | -1.91M | -1.53M | -5.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.33M | -1.92M | -1.91M | -1.53M | -5.25M |
| EBIT | -1.56M | -1.94M | -1.60M | -1.58M | -1.84M |
| EBITDA | -1.55M | -1.93M | -1.60M | -1.58M | -1.82M |
| EPS Basic | -3.10 | -4.50 | -4.56 | -5.93 | -15.47 |
| Normalized Basic EPS | -2.28 | -2.81 | -2.74 | -2.64 | -3.50 |
| EPS Diluted | -3.10 | -4.50 | -4.56 | -5.93 | -15.47 |
| Normalized Diluted EPS | -2.28 | -2.81 | -2.74 | -2.64 | -3.50 |
| Average Basic Shares Outstanding | 427.10K | 427.10K | 418.90K | 362.40K | 339.10K |
| Average Diluted Shares Outstanding | 427.10K | 427.10K | 418.90K | 362.40K | 339.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |